Inovio Pharmaceuticals’ (INO) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $3.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($2.12) EPS.

Separately, JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $12.20.

Inovio Pharmaceuticals Trading Down 1.0 %

INO stock opened at $1.92 on Wednesday. The firm has a 50-day moving average price of $2.04 and a 200-day moving average price of $3.71. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75. The stock has a market capitalization of $50.11 million, a P/E ratio of -0.91 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.18. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its stake in shares of Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 3,630 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares during the period. Alpine Global Management LLC bought a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at about $31,000. Atom Investors LP acquired a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at about $103,000. Finally, Bank of Montreal Can bought a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth about $43,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.